Article

Modified steroid has 'potential' for treating subfoveal CNV in AMD

Author(s):

Fort Lauderdale, FL-Anecortave acetate (Alcon), a chemically modified steroid, acts in a unique way to suppress abnormal blood vessel growth in patients with subfoveal choroidal neovascularization (CNV) associated with age-related macular degeneration (AMD).

Related Videos
Ophthalmology Times: Kathryn Colby, MD, PhD, reflects on National Women Physicians Day
2 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
© 2025 MJH Life Sciences

All rights reserved.